Metformin-Induced Generalized Bullous Fixed-Drug Eruption with a Positive Dechallenge-Rechallenge Test: A Case Report and Literature Review

Bahareh Abtahi-Naeini; Tooba Momen; Rezvan Amiri; Parvin Rajabi; Fereshte Rastegarnasab

doi:10.1155/2023/6353919

Metformin-Induced Generalized Bullous Fixed-Drug Eruption with a Positive Dechallenge-Rechallenge Test: A Case Report and Literature Review

Case Rep Dermatol Med. 2023 Mar 31:2023:6353919. doi: 10.1155/2023/6353919. eCollection 2023.

Authors

Bahareh Abtahi-Naeini^{1

2}, Tooba Momen³, Rezvan Amiri⁴, Parvin Rajabi⁵, Fereshte Rastegarnasab⁶

Affiliations

¹ Pediatric Dermatology Division of Department of Pediatrics, Imam Hossein Children's Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
² Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
³ Department of Asthma, Allergy and Clinical Immunology, Child Growth and Development Research Center, Research Institute of Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran.
⁴ Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
⁵ Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
⁶ Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran.

Abstract

Metformin is a commonly used medication in diabetic patients. It can cause different complications including cutaneous adverse reactions. Metformin-induced fixed-drug eruption (FDE) has been reported in limited cases. Due to the popularity of metformin, clinicians need to be aware of uncommon drug reactions for proper diagnosis and treatment. Herein, we report a 43-year-old man with generalized bullous lesions with a positive dechallenge-rechallenge test diagnosed as metformin-induced generalized bullous fixed-drug eruption. Metformin dosage was stopped and lesions were treated with topical clobetasol propionate and oral prednisolone and cyclosporine-A. After a 6-month follow-up, he was well without any relapsing episodes.

Publication types

Case Reports